REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
02/09/2026
Back to search
Official data from USPTO
MIDATECH PHARMA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
31
Latest update
02/10/2026
Classification
Registered
Trademark type
Combined
Nice classes
1, 5, 40, 42
Filing date
11/14/2019
Registration date
02/09/2021
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/09/2021
Last transaction
02/10/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
99
Owner location
GB
Examiner
RENNEKER, CHRISTOPHER JOHN
Law office
N30
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the wording "MIDATECH" in dark blue above the wording "PHARMA" in light blue. Next to the wording starts an incomplete circular array of light and blue dots that bend towards the letter "E" in "MIDATECH". White appearing in the mark is background and not claimed as a feature of the mark.
Holders and representatives
Holders
Midatech Limited
Representatives
Manuel Valcarcel Greenberg Traurig, P.A.
Technical classification
Nice Classes
Class 1Class 5Class 40Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Active chemical ingredients for use in the manufacture of pharmaceuticals, cosmetics and medicines for treating viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system and central nervous system related diseases and disorders; nano-particle ingredients for use in pharmaceuticals, medicines and medicated cosmetics for treating viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system and central nervous system related diseases and disorders
Class 5
Pharmaceutical preparations and medicines containing nano-particles for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system and central nervous system related diseases and disorders; vaccines incorporating nano-particles
Class 40
Custom manufacture of nano-particles for use in the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system and central nervous system related diseases and disorders; custom manufacture of pharmaceuticals and medicines containing nano-particles; custom manufacture of nano-particle devices for use in the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system and central nervous system related diseases and disorders
Class 42
Scientific research services for others in the field of nano-particle technology; pharmaceutical and drug development and drug discovery services; scientific laboratory services, namely, testing, efficiency evaluation and advisory services in the field of nano-particles and nano-medicine; scientific laboratory services, namely, testing, efficiency and technical and scientific advisory services in the field of pharmaceuticals; scientific research laboratory services, namely, nano-particle laboratory services
Publications
History of USPTO decisions and trademark events.
31 publications found
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
06/07/2021
FICS
FINAL DISPOSITION NOTICE SENT TO IB
05/12/2021
FIMP
FINAL DISPOSITION PROCESSED
05/12/2021
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
05/09/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
02/09/2021
GPNX
NOTIFICATION PROCESSED BY IB
12/06/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/24/2020
PUBO
PUBLISHED FOR OPPOSITION
11/24/2020
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
11/18/2020
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
11/18/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/04/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/16/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/23/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/23/2020
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
09/23/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
09/23/2020
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
09/23/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
09/23/2020
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
09/23/2020
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
09/23/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/23/2020
RFNT
REFUSAL PROCESSED BY IB
04/18/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
03/28/2020
RFRR
REFUSAL PROCESSED BY MPU
03/27/2020
MAFR
APPLICATION FILING RECEIPT MAILED
03/17/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
03/12/2020
CNRT
NON-FINAL ACTION WRITTEN
03/11/2020
DOCK
ASSIGNED TO EXAMINER
03/11/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/11/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
03/05/2020
Continuous trademark protection
Get notified about every new filing that threatens MIDATECH PHARMA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.